Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healt...
20 Février 2019 - 12:30PM
Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage
biopharmaceutical company innovating treatments for people with
ultra-rare bone disorders and other diseases, today announced that
management will host a conference call in conjunction with the
announcement of its fourth quarter and full-year 2018 financial
results and present at the 8th Annual SVB Leerink Partners
Healthcare Conference. Details of the events are as follows:
- Fourth Quarter and Full-Year 2018 Financial
Results: Management will host a conference call and
webcast to discuss its fourth quarter and full year 2018 financial
results and other business highlights at 7:30 a.m. ET on Thursday,
February 28, 2019. To participate in the conference call, please
dial (866) 916-2014 (domestic) or (636) 812-6655 (international)
and refer to conference ID 9098109.
- 8th Annual SVB Leerink Global Healthcare Conference
Presentation: Management will present a company overview
at the 8th Annual SVB Leerink Global Healthcare Conference on
Thursday, February 28, 2019 at 2:30 p.m. ET in New York.
Live webcasts will be available in the investor section of the
company's website at www.clementiapharma.com. The webcasts also
will be archived for 60 days following the call and
presentation.
About Clementia Pharmaceuticals
Inc.Clementia is a clinical-stage company innovating
treatments for people with ultra-rare bone disorders and other
diseases with high medical need. The company is preparing to submit
an NDA in the second half of 2019 to seek approval of its lead
product candidate, palovarotene, a novel RARγ agonist, for
fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3
MOVE Trial is evaluating an additional dosing regimen of
investigational palovarotene for FOP. Palovarotene is also in a
Phase 2 trial, the MO-Ped Trial, for the potential treatment of
multiple osteochondromas (MO, also known as multiple hereditary
exostoses, or MHE). In addition, Clementia has commenced a Phase 1
trial for an eye drop formulation of palovarotene for the potential
treatment of dry eye disease and is also investigating other
conditions that may benefit from RARγ therapy. For more
information, please visit www.clementiapharma.com and connect
with us on Twitter @ClementiaPharma.
Investor/Media Contact:
Joseph WalewiczClementia Pharmaceuticals Inc.+1-514-940-1080
Alicia Davis THRUST Strategic Communications +1-910-620-3302
alicia@thrustsc.com
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Clementia Pharmaceuticals Inc. (NASDAQ): 0 recent articles
Plus d'articles sur